STOCK TITAN

Genprex, Inc. - GNPX STOCK NEWS

Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.

Genprex, Inc. (NASDAQ: GNPX) is a pioneering clinical-stage gene therapy company committed to transforming the landscape of cancer and diabetes treatments. The company's mission is to address the unmet medical needs of a growing population of patients worldwide through the development of innovative immunogene therapies. Genprex's flagship product, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is at the forefront of its oncology program and is currently being evaluated in three clinical trials targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Oncoprex® Delivery System, Genprex's proprietary platform, encapsulates gene-expressing plasmids using lipid-based nanoparticles. This systemic, non-viral method enables the intravenous delivery of tumor suppressor genes to cancer cells, which then express proteins that were deficient in the tumor. Reqorsa Immunogene Therapy has shown promise by re-establishing pathways for programmed cell death, interrupting cancer cell signaling, and modulating immune responses.

The company's recent achievements include securing new patents and receiving FDA Fast Track and Orphan Drug designations for its clinical programs. Specifically, the Acclaim-2 and Acclaim-3 studies are exploring the potential of Reqorsa in combination with immune checkpoint inhibitors like Keytruda® and Tecentriq®. These trials aim to provide new therapeutic options for patients with advanced-stage lung cancers who have limited treatment alternatives.

In addition to its oncology initiatives, Genprex is advancing a novel gene therapy approach for diabetes. Using an AAV vector, the company delivers Pdx1 and MafA genes directly to the pancreas to transform alpha cells into beta-like cells capable of producing insulin. This method shows promise for both Type 1 and Type 2 diabetes and aims to offer a new lifeline for patients with these conditions.

Genprex collaborates with renowned institutions and industry leaders to further its research and development pipeline. The company's commitment to innovation and patient-centric solutions positions it as a significant player in the gene therapy landscape.

Latest News:

  • March 12, 2024 - Genprex announces new patent grants in South Korea for Reqorsa® Immunogene Therapy.
  • March 19, 2024 - Genprex enters into agreements for the sale and issuance of shares, expecting gross proceeds of $6.5 million.
  • April 2, 2024 - Positive preclinical data for NPRL2 gene therapy presented at AACR Annual Meeting.
  • April 3, 2024 - Multiple new trial sites added for Acclaim-3 study in extensive-stage small cell lung cancer.
  • April 9, 2024 - Research collaborators present positive preclinical data supporting Reqorsa and NPRL2 therapies.
  • May 8, 2024 - Genprex announces the passing of its co-founder and CEO Rodney Varner.
  • May 14, 2024 - First patient dosed in Phase 1 of Acclaim-3 clinical study for Reqorsa® and Tecentriq® combination therapy.
Rhea-AI Summary

Genprex (NASDAQ: GNPX) announced that its research collaborators will present positive preclinical data on Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium. The presentations will focus on Reqorsa as a potential treatment for Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma. Three posters will be presented, showcasing studies conducted with academic partners.

Genprex has filed two provisional patent applications based on the data, one for treating mesothelioma and another for glioblastoma. The company is co-owner of these applications with the respective institutions. Reqorsa uses the TUSC2 tumor suppressor gene encapsulated in non-viral lipid-based nanoparticles, designed to target cancer cells while minimizing uptake by normal tissue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences clinical trial
-
Rhea-AI Summary

Genprex (NASDAQ: GNPX) has announced plans to create a new subsidiary focused on developing GPX-002, a gene therapy for Type 1 and Type 2 diabetes. This move aims to separate the diabetes program from Genprex's oncology portfolio, potentially attracting more investors and expediting clinical development. The spin-out is expected to occur by the end of 2024, subject to financing and board approval.

The new company would become a pure-play diabetes-focused biopharmaceutical entity, while Genprex would concentrate on oncology. GPX-002, licensed from the University of Pittsburgh, uses an AAV vector containing Pdx1 and MafA genes administered directly into the pancreatic duct. This approach could potentially replace daily blood glucose monitoring and insulin therapy, as well as GLP-1 treatments in Type 2 diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.7%
Tags
none
-
Rhea-AI Summary

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, has announced its participation in two major investor and industry conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-13, with an on-demand virtual presentation by Ryan Confer, Genprex's President, CEO, and CFO, available from September 9-11.

Additionally, Genprex will attend Chardan's 8th Annual Genetic Medicines Conference from September 30 to October 1 in New York City. Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will be available for in-person meetings at this event. These presentations will highlight Genprex's innovative gene therapies for cancer and diabetes, offering investors insights into the company's progress and potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
conferences
Rhea-AI Summary

Genprex (NASDAQ: GNPX) has released a new video featuring Chief Medical Officer Dr. Mark Berger discussing positive patient outcomes in two lung cancer clinical trials. The Acclaim-1 trial, evaluating Reqorsa® Gene Therapy with Tagrisso® for late-stage NSCLC, showed remarkable prolonged Progression Free Survival in two patients. In the Acclaim-3 trial, testing Reqorsa with Tecentriq® for extensive stage small cell lung cancer, the first patient achieved a partial remission during maintenance therapy.

Dr. Berger highlighted the significance of these results and announced updates to the oncology clinical development program. Genprex is streamlining its efforts by removing a cohort in Acclaim-1's Phase 2a and closing Acclaim-2 to further enrollment due to slow recruitment. The company aims to focus resources on advancing Reqorsa through the clinic efficiently.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Genprex (NASDAQ: GNPX) announced positive updates for its Acclaim-1 and Acclaim-3 clinical trials treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with Reqorsa® Gene Therapy. In Acclaim-1, two patients showed prolonged Progression Free Survival, with one maintaining a Partial Remission for over two years. The first patient in Acclaim-3 achieved a Partial Remission during maintenance therapy.

Genprex is refocusing its oncology program, discontinuing Acclaim-2 and limiting Acclaim-1's Phase 2a to patients with prior Tagrisso treatment only. The company expects to complete enrollment for Acclaim-1's Phase 2a first 19 patients and conduct an interim analysis in H1 2025. Acclaim-3's Phase 2 expansion is anticipated to start in H2 2024.

Genprex is also collaborating with an academic partner to develop biomarkers for patient selection and treatment response prediction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Genprex (NASDAQ: GNPX) has been granted a patent in Singapore for its lead drug candidate, Reqorsa® Gene Therapy, in combination with anti-PD-1 antibodies for cancer treatment. This patent, valid through 2037, expands on previously granted patents in other countries and covers the use of REQORSA with immune checkpoint inhibitors. The company plans to pursue additional patents for REQORSA combined with PD-L1 antibodies in various countries, which could apply to their Acclaim-3 clinical trial.

The patent strengthens Genprex's intellectual property portfolio, particularly in Asian markets where lung cancer is prevalent. In 2022, Asia accounted for 63% of new lung cancer cases worldwide. The Acclaim-3 study, a Phase 1/2 clinical trial, combines REQORSA with Genentech's Tecentriq® for extensive stage small cell lung cancer (ES-SCLC) patients. This trial has received FDA Fast Track Designation and Orphan Drug Designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Sidoti Microcap Conference on August 15, 2024, at 8:30 am ET. Ryan Confer, the company's President, CEO, and CFO, will provide an overview of Genprex's gene therapies for cancer and diabetes.

The virtual presentation will highlight the company's pioneering work in developing life-changing therapies. Investors can access the presentation through a provided link and schedule virtual meetings with Mr. Confer. An archive of the presentation will be available on the company's website in the Investor Relations section.

This conference appearance underscores Genprex's commitment to advancing its innovative gene therapy pipeline and engaging with the investment community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
conferences
-
Rhea-AI Summary

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announced significant achievements in its 2024 stockholder letter. The company has initiated two new lung cancer clinical trials and continues treating patients in an ongoing trial. By partnering with community-based oncology practices, Genprex aims to extend its clinical reach. They have also expanded preclinical research into new therapeutic areas, showcasing positive results at a major cancer conference. Additionally, their global intellectual property portfolio has been strengthened to protect their lead drug candidate. Genprex is optimistic about upcoming catalysts that will enhance its position in gene therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Summary

Genprex, a clinical-stage gene therapy company, announced its participation in the 2024 BIO International Convention, set to take place from June 3-6, 2024, at the San Diego Convention Center. The company's President, CEO, and CFO, Ryan Confer, will present on June 3 at 2:00 p.m. PT. The presentation will cover Genprex's gene therapies for cancer and diabetes. Attendees can request one-on-one meetings through the conference portal or by contacting Investor Relations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
conferences
Rhea-AI Summary

Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, is supported by FDA Orphan Drug and Fast Track designations. Genprex highlighted the poor prognosis of ES-SCLC and the benefits of current treatments, emphasizing the potential of their therapy. Positive outcomes from the Phase 1 Acclaim-1 study in non-small cell lung cancer have enabled an accelerated timeline for Acclaim-3.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.53%
Tags

FAQ

What is the current stock price of Genprex (GNPX)?

The current stock price of Genprex (GNPX) is $1.04 as of December 6, 2024.

What is the market cap of Genprex (GNPX)?

The market cap of Genprex (GNPX) is approximately 8.9M.

What is Genprex's main focus?

Genprex focuses on developing gene therapies for cancer and diabetes, aiming to address unmet medical needs with innovative treatments.

What is Reqorsa Immunogene Therapy?

Reqorsa Immunogene Therapy is Genprex's lead product candidate, which uses a gene-expressing plasmid encapsulated in lipid nanoparticles to target cancer cells.

How does the Oncoprex® Delivery System work?

The Oncoprex® Delivery System utilizes lipid-based nanoparticles to encapsulate and deliver gene-expressing plasmids to cancer cells, restoring tumor suppressor proteins.

What recent achievements has Genprex made?

Genprex has secured new patents, received FDA Fast Track and Orphan Drug designations, and presented positive preclinical data at major conferences.

What is the status of Genprex's clinical trials?

Genprex is currently evaluating Reqorsa in three clinical trials for NSCLC and SCLC, with ongoing studies like Acclaim-2 and Acclaim-3 showing promising results.

What are the implications of Genprex's recent patent grants?

The new patents expand Genprex's intellectual property portfolio, securing exclusivity for Reqorsa's use in combination with immune checkpoint inhibitors in major markets.

What is Genprex's approach to diabetes treatment?

Genprex uses an AAV vector to deliver Pdx1 and MafA genes to the pancreas, transforming alpha cells into beta-like cells that can produce insulin for Type 1 and Type 2 diabetes.

How does Reqorsa enhance current cancer treatments?

Reqorsa works synergistically with approved treatments like Keytruda and Tecentriq, potentially improving outcomes for patients with advanced lung cancers.

Who are Genprex's key collaborators?

Genprex collaborates with world-class institutions and industry leaders to advance its gene therapy research and development pipeline.

How has Genprex adapted to recent leadership changes?

Following the passing of co-founder Rodney Varner, Genprex's Board appointed Ryan Confer as President and CEO to ensure continuity and uphold the company's mission.

Genprex, Inc.

Nasdaq:GNPX

GNPX Rankings

GNPX Stock Data

8.94M
8.34M
6.4%
10.91%
14.04%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
AUSTIN